title: Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin.
abstract: OBJECTIVE
  Aminopenicillin-induced exanthema poses a problem in the management of infectious diseases. Due to theoretically possible immunological cross-reactivity, all beta-lactam drugs, i.e. penicillins, penicillin derivatives and cephalosporins, are usually avoided. The available alternative antibiotics (macrolides, quinolones and glycopeptides) may be less effective, have more side effects, and their use increases medical costs. Moreover, their use contributes to the increasing bacterial resistance to antibiotics. The aim of the study is to demonstrate that patients with aminopenicillin-induced exanthema may receive specific beta-lactams for future antibiotic therapy.
  
  
  METHODS
  Skin testing followed by oral challenges to identify beta-lactams that are tolerated by patients despite confirmed delayed-type non-immunoglobulin E (IgE)-mediated allergic hypersensitivity to aminopenicillins.
  
  
  RESULTS
  Sixty-nine out of 71 patients (97.2%) with non-IgE-mediated allergic hypersensitivity to aminopenicillins tolerate cephalosporins without an aminobenzyl side chain such as cefpodoxime or cefixime and 51 patients (71.8%) also tolerate phenoxymethyl penicillin.
  
  
  CONCLUSIONS
  The majority of patients with non-IgE-mediated allergic hypersensitivity to aminopenicillins do not cross-react to certain cephalosporins or phenoxymethyl penicillin. Skin and drug challenge tests can be helpful to determine individual cross-reactivity.
authors.affiliation: Department of Dermatology, Venerology and Allergology, University of Würzburg, Würzburg, Germany.
authors.forename: Jiri
authors.initials: J
authors.lastname: Trcka
authors.forename: Cornelia S
authors.initials: CS
authors.lastname: Seitz
authors.forename: Eva-B
authors.initials: EB
authors.lastname: Bröcker
authors.forename: Gerd E
authors.initials: GE
authors.lastname: Gross
authors.forename: Axel
authors.initials: A
authors.lastname: Trautmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D020682:Cefixime / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D015296:Ceftizoxime / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D002511:Cephalosporins / Q000737:chemistry / Q000627:therapeutic use*; D003429:Cross Reactions; D004342:Drug Hypersensitivity / Q000188:drug therapy* / Q000209:etiology; D005076:Exanthema / Q000139:chemically induced / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000188:drug therapy* / Q000209:etiology; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D008875:Middle Aged; D010404:Penicillin V / Q000737:chemistry / Q000627:therapeutic use*; D016037:Single-Blind Method; D012882:Skin Tests; D016896:Treatment Outcome; D047090:beta-Lactams / Q000737:chemistry / Q000627:therapeutic use; D000097623:Cefpodoxime
chemical_list: D000658:Amoxicillin; D000900:Anti-Bacterial Agents; D020682:Cefixime; D015296:Ceftizoxime; D002511:Cephalosporins; D007073:Immunoglobulin E; D010404:Penicillin V; D047090:beta-Lactams; D000097623:Cefpodoxime